title: Clinical response of newly diagnosed HIV seropositive & seronegative pulmonary tuberculosis patients with the RNTCP Short Course regimen in Pune, India.
abstract: OBJECTIVE
  In the Revised National Tuberculosis Control Programme (RNTCP) in India prior to 2005, TB patients were offered standard DOTS regimens without knowledge of HIV status. Consequently such patients did not receive anti-retroviral therapy (ART) and the influence of concomitant HIV infection on the outcome of anti-tuberculosis treatment remained undetermined. This study was conducted to determine the results of treatment of HIV seropositive pulmonary tuberculosis patients with the RNTCP (DOTS) regimens under the programme in comparison with HIV negative patients prior to the availability of free ART in India.
  
  
  METHODS
  Between September 2000 and July 2006, 283 newly diagnosed pulmonary TB patients were enrolled in the study at the TB Outpatient Department at the Talera Hospital in the Pimpri Chinchwad Municipal Corporation area at Pune (Maharashtra): they included 121 HIV seropositive and 162 HIV seronegative patients. They were treated for tuberculosis as per the RNTCP in India. This study was predominantly conducted in the period before the free ART become available in Pune.
  
  
  RESULTS
  At the end of 6 months of anti-TB treatment, 62 per cent of the HIV seropositive and 92 per cent of the HIV negative smear negative patients completed treatment and were asymptomatic; among smear positive patients, 70 per cent of the HIV-seropositive and 81 per cent of HIV seronegative pulmonary TB patients were cured. Considering the results in the smear positive and smear negative cases together, treatment success rates were substantially lower in HIV positive patients than in HIV negative patients, (66% vs 85%). Further, 29 per cent of HIV seropositive and 1 per cent of the HIV seronegative patients expired during treatment. During the entire period of 30 months, including 6 months of treatment and 24 months of follow up, 61 (51%) of 121 HIV positive patients died; correspondingly there were 6 (4%) deaths among HIV negative patients.
  
  
  CONCLUSIONS
  The HIV seropositive TB patients responded poorly to the RNTCP regimens as evidenced by lower success rates with chemotherapy and high mortality rates during treatment and follow up. There is a need to streamline the identification and management of HIV associated TB patients in the programme with provision of ART to achieve high cure rates for TB, reducing mortality rates and ensuring a better quality of life.
authors.affiliation: National AIDS Research Institute (ICMR), Pune, India. stripathy@nariindia.org
authors.forename: S
authors.initials: S
authors.lastname: Tripathy
authors.forename: A
authors.initials: A
authors.lastname: Anand
authors.forename: V
authors.initials: V
authors.lastname: Inamdar
authors.forename: M M
authors.initials: MM
authors.lastname: Manoj
authors.forename: K M
authors.initials: KM
authors.lastname: Khillare
authors.forename: A S
authors.initials: AS
authors.lastname: Datye
authors.forename: R
authors.initials: R
authors.lastname: Iyer
authors.forename: D M
authors.initials: DM
authors.lastname: Kanoj
authors.forename: M
authors.initials: M
authors.lastname: Thakar
authors.forename: V
authors.initials: V
authors.lastname: Kale
authors.forename: M
authors.initials: M
authors.lastname: Pereira
authors.forename: A R
authors.initials: AR
authors.lastname: Risbud
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003140:Communicable Disease Control / Q000379:methods / Q000706:statistics & numerical data; D023801:Directly Observed Therapy; D004797:Enzyme-Linked Immunosorbent Assay; D004977:Ethambutol / Q000008:administration & dosage / Q000627:therapeutic use; D018023:HIV Seronegativity; D006679:HIV Seropositivity; D006801:Humans; D007194:India; D007538:Isoniazid / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D011718:Pyrazinamide / Q000008:administration & dosage / Q000627:therapeutic use; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000821:virology
chemical_list: D000995:Antitubercular Agents; D011718:Pyrazinamide; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin